Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat for GVHD Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic BMT
NCT03842696Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2020
- Primary completion
- Jul 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in graft-versus-host disease (GVHD), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Recommended Phase 2 Dose and Incidence of grade 2-4 acute GVHD. Started Feb 2020; status: active, not recruiting.
02
Drugs
vorinostat
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03842696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842696.